Abstract 4402: EGFR and LGR5 dual-targeting antibody-drug conjugate-based therapeutic strategies for the improved treatment of colorectal cancer

作者
Peyton C. High,Zhengdong Liang,Maya G. Cappellino,Tiffani A. Blackburn,Cara Guernsey-Biddle,Shraddha Subramanian,Yueh-Ming Shyu,Adela M. Aldana,Yukimatsu Toh,Kendra S. Carmon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 4402-4402
标识
DOI:10.1158/1538-7445.am2026-4402
摘要

Abstract Colorectal cancer (CRC) remains the second-leading cause of cancer-associated death in the United States, indicating an urgent need for improved therapies. Antibody-drug conjugates (ADCs) are a promising class of therapeutics that function as “biological missiles,” employing the specificity of monoclonal antibodies to direct highly potent drug payloads to cancer cells while sparing normal tissues. We have developed ADCs targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a marker of normal adult intestinal stem cells and CRC stem-like cells with roles in CRC tumorigenesis, tumor progression, metastasis, and drug resistance. While LGR5-targeting ADCs incorporating microtubule inhibitors promoted tumor regression in select xenograft models and were well-tolerated, tumors eventually relapse following treatment cessation due to LGR5 downregulation and suboptimal ADC payload selection (Gong et al. 2016, Molecular Cancer Therapeutics). Thus, this work aims to investigate multi-targeting therapeutic strategies with improved LGR5-targeting ADCs to improve CRC care and prevent relapse. Our work showed that therapies targeting the epidermal growth factor receptor (EGFR), including cetuximab (CTX) which is approved for KRASWTmetastatic CRC, increased LGR5 protein levels in CRC cell lines, tumor organoids, and mouse models independent of KRAS mutational status. To evaluate EGFR and LGR5 dual-targeting approaches, we generated a novel LGR5-targeting ADC incorporating a topoisomerase I inhibitor payload via site-specific conjugation that was well-tolerated in immunocompetent mice. Importantly, combination of CTX with LGR5-targeting ADCs significantly enhanced anti-tumor efficacy and extends survival as compared to ADC and CTX monotherapies in RASMUT CRC patient-derived xenografts (High et al. 2025, Cell Reports Medicine). Still, tumors eventually relapsed following combination treatment, warranting investigation into alternative dosing regimens and dual-targeting modalities. We have therefore generated two EGFR:LGR5 bispecific antibodies (bsAbs) that promote lysosome-mediated EGFR degradation. EGFR:LGR5 bsAbs demonstrated minimal cytotoxicity in CRC cells, necessitating drug conjugation to generate highly potent EGFR:LGR5 bispecific ADCs (bsADCs). Importantly, EGFR:LGR5 bsADCs exert 100- to 1000-fold enhanced potency over LGR5 ADCs with identical linker-payloads in LGR5/EGFR-expressing CRC cell lines of varying genetic backgrounds. These promising findings warrant further investigation into the anti-tumor efficacy of EGFR:LGR5 bsADC monotherapy versus combination therapy of CTX and LGR5 ADCs in CRC xenograft models. Taken together, this work strongly rationalizes dual-targeting of EGFR and LGR5 as an effective therapeutic option for CRC and other EGFR- and LGR5-expressing cancers. Citation Format: Peyton C. High, Zhengdong Liang, Maya Cappellino, Tiffani Blackburn, Cara Guernsey-Biddle, Shraddha Subramanian, Yueh-Ming Shyu, Adela Aldana, Yukimatsu Toh, Kendra S. Carmon. EGFR and LGR5 dual-targeting antibody-drug conjugate-based therapeutic strategies for the improved treatment of colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4402.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zz发布了新的文献求助200
1秒前
cdercder的应助被开心德地采纳,获得10
2秒前
水煮电吹风的应助被liu采纳,获得10
3秒前
海阔天空发布了新的文献求助10
3秒前
酷波er的应助被小燕尾条采纳,获得10
4秒前
单薄冰安发布了新的文献求助10
5秒前
5秒前
常濪完成签到 ,获得积分10
7秒前
CipherSage的应助被yu采纳,获得10
7秒前
大庆完成签到,获得积分10
9秒前
研友_VZG7GZ的应助被温暖砖头采纳,获得10
10秒前
33333完成签到,获得积分10
10秒前
春桑早点睡完成签到,获得积分10
11秒前
超超发布了新的文献求助10
12秒前
13秒前
徵宇完成签到,获得积分10
13秒前
14秒前
GL完成签到,获得积分10
15秒前
Mine完成签到,获得积分20
15秒前
深情安青的应助被dididi采纳,获得10
15秒前
安赛虫完成签到,获得积分10
16秒前
xing完成签到,获得积分10
17秒前
CipherSage的应助被hefang采纳,获得10
17秒前
yu发布了新的文献求助10
18秒前
cdercder的应助被开心德地采纳,获得10
18秒前
贾贡献的应助被学术bug采纳,获得10
19秒前
yyf完成签到,获得积分10
19秒前
19秒前
森煜完成签到,获得积分10
21秒前
所所的应助被幽默的羿采纳,获得10
22秒前
23秒前
加油完成签到,获得积分10
23秒前
Fun_112发布了新的文献求助30
23秒前
一十七完成签到 ,获得积分10
25秒前
顾矜的应助被淡淡新竹采纳,获得10
26秒前
Hao发布了新的文献求助10
26秒前
cdercder的应助被开心德地采纳,获得10
26秒前
盒子的应助被是小刘同学呀采纳,获得30
26秒前
27秒前
科研通AI65的应助被wg采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188724
求助须知:如何正确求助?哪些是违规求助? 9576405
关于积分的说明 21847400
捐赠科研通 7786785
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559647
邀请新用户注册赠送积分活动 2482363